Tesaro (TSRO) PT Raised to $120 at Baird

October 10, 2016 7:51 AM EDT
Get Alerts TSRO Hot Sheet
Price: $117.80 +1.55%

Rating Summary:
    14 Buy, 2 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade TSRO Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Baird analyst Michael Ulz reiterated an Outperform rating and raised his price target on Tesaro (NASDAQ: TSRO) to $120.00 (from $105.00) with full niraparib data better than expected.

Ulz commented, "Over the weekend, detailed data from the Phase 3 NOVA study of niraparib in 2L+ maintenance of ovarian cancer were presented at the ESMO meeting and published in the NEJM. Overall, the updated data further strengthens niraparib's market-leading position, supporting broad use across all platinum-sensitive patients with a manageable safety profile. Filing remains on track to complete in 4Q16, and we continue to anticipate approval in 1H17. We reiterate our Outperform rating and raise our price target to $120."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Robert W Baird

Add Your Comment